Quantcast

Latest Docetaxel Stories

2011-09-26 11:11:04

The first randomized trial to investigate the use of trastuzumab emtansine (T-DM1) — an antibody-guided drug — for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening. Dr Sara Hurvitz, one of the trial investigators, will tell the 2011 European Multidisciplinary Cancer Congress in Stockholm today (Sunday 25 September):...

2011-08-26 07:00:00

Premiere Oncology today announced that it is participating in a Phase 2b/3 clinical trial of ganetespib, a novel, potent anti-cancer drug in combination with docetaxel, an approved chemotherapy drug, for the treatment of non-small cell lung cancer patients. Santa Monica, CA (PRWEB) August 26, 2011 Ganetespib is the most advanced drug candidate in a new class of anti-cancer drugs called heat shock protein (Hsp) 90 inhibitors. Hsp90 is a molecular chaperone required for the proper folding...

2011-07-07 06:00:00

TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP(TM) (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns. This decision is based on the recommendation of an Independent Data...

2011-06-27 15:37:00

THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone. The...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related